Eftilagimod alfa

DB16150InvestigationalProtein Based Therapies

Eftilagimod alfa is under investigation in clinical trial NCT02614833 (IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma).

Mechanism: Pharmacologically active on Lymphocyte activation gene 3 protein
Curator reviewed
Also known as: Immufact
Code names: EFTI · IMP321

Resolves to

Compound

UNIISJ82PK3HWACAS1800476-36-1

Targets

P18627LAG3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

15Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eftilagimod alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account